• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Optinose

anonymous

Guest
New VP of sales is coming from Sun where he failed miserably, talks negatively about gays, and loves to check out the young skirts. He also is going to bring all of his ex J & J cronies with him. Buyer beware if you come to Optinose. One of the biggest ego maniacs there is and you can't trust him. Besides that he is great.
 




































It might be sad, but it also rather amusing. They think they are geniuses, especially those hopping on board now. The Johnny come lately crew who have done nothing but cash a paycheck. Watch how quickly they burn through that hundred million.
 




















Sure, that's it, I am just mad that I didn't get the job. My dream has always been to work with a bunch of losers that couldn't cut it anywhere else. To think that their fearless leader thinks that he hired all of the "nice" ones...I'm sure he would love to know he hired a years long Ashley Madison member!! Funny how the man who wouldn't take a position unless it was a "senior director" was convinced to troll indeed.com for a job. Amazing how quickly your standards drop after a couple years of unemployment...
 
















We are on a roll!

First Quarter 2018 Financial Results
Revenue
The Company generated $0.9 million in net revenue through the sales of XHANCE in the three-month period ended March 31, 2018. A large majority of the revenue corresponded with the stocking of the retail distribution channel, with a portion of the revenue related to XHANCE sales through the Xperience program.

Operating expenses and net loss
For the three-month period ended March 31, 2018, research and development expenses were $1.7 million and selling, general and administrative expenses totaled $28.0 million. Net loss for the period was $30.6 million, or $0.81 per share.